Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Thumb Arthritis Market

ID: MRFR/MED/3800-HCR
90 Pages
Rahul Gotadki
Last Updated: May 15, 2026

Thumb Arthritis Market Research Report Information By Diagnosis (Physical Examinations, Imaging, FNA), By Type (Osteoarthritis, Rheumatoid), By Treatment (Thumb Exercise, Medication, Surgery), By End Users (Hospitals & Clinics, Retail Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type of Arthritis (USD Million)
      1. 4.1.1 Osteoarthritis
      2. 4.1.2 Rheumatoid Arthritis
      3. 4.1.3 Post-Traumatic Arthritis
      4. 4.1.4 Gout
    2. 4.2 Healthcare, BY Treatment Type (USD Million)
      1. 4.2.1 Medication
      2. 4.2.2 Physical Therapy
      3. 4.2.3 Surgical Intervention
      4. 4.2.4 Assistive Devices
    3. 4.3 Healthcare, BY Age Group (USD Million)
      1. 4.3.1 Children
      2. 4.3.2 Adults
      3. 4.3.3 Elderly
    4. 4.4 Healthcare, BY Severity Level (USD Million)
      1. 4.4.1 Mild
      2. 4.4.2 Moderate
      3. 4.4.3 Severe
    5. 4.5 Healthcare, BY Region (USD Million)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Johnson & Johnson (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Medtronic (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Stryker Corporation (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Zimmer Biomet (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Abbott Laboratories (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Baxter International (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Smith & Nephew (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Boston Scientific (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 DePuy Synthes (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TYPE OF ARTHRITIS
    4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
    5. 6.5 US MARKET ANALYSIS BY AGE GROUP
    6. 6.6 US MARKET ANALYSIS BY SEVERITY LEVEL
    7. 6.7 CANADA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    9. 6.9 CANADA MARKET ANALYSIS BY AGE GROUP
    10. 6.10 CANADA MARKET ANALYSIS BY SEVERITY LEVEL
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF ARTHRITIS
    13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    14. 6.14 GERMANY MARKET ANALYSIS BY AGE GROUP
    15. 6.15 GERMANY MARKET ANALYSIS BY SEVERITY LEVEL
    16. 6.16 UK MARKET ANALYSIS BY TYPE OF ARTHRITIS
    17. 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE
    18. 6.18 UK MARKET ANALYSIS BY AGE GROUP
    19. 6.19 UK MARKET ANALYSIS BY SEVERITY LEVEL
    20. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF ARTHRITIS
    21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    22. 6.22 FRANCE MARKET ANALYSIS BY AGE GROUP
    23. 6.23 FRANCE MARKET ANALYSIS BY SEVERITY LEVEL
    24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    26. 6.26 RUSSIA MARKET ANALYSIS BY AGE GROUP
    27. 6.27 RUSSIA MARKET ANALYSIS BY SEVERITY LEVEL
    28. 6.28 ITALY MARKET ANALYSIS BY TYPE OF ARTHRITIS
    29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    30. 6.30 ITALY MARKET ANALYSIS BY AGE GROUP
    31. 6.31 ITALY MARKET ANALYSIS BY SEVERITY LEVEL
    32. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF ARTHRITIS
    33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    34. 6.34 SPAIN MARKET ANALYSIS BY AGE GROUP
    35. 6.35 SPAIN MARKET ANALYSIS BY SEVERITY LEVEL
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF ARTHRITIS
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY SEVERITY LEVEL
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    43. 6.43 CHINA MARKET ANALYSIS BY AGE GROUP
    44. 6.44 CHINA MARKET ANALYSIS BY SEVERITY LEVEL
    45. 6.45 INDIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    47. 6.47 INDIA MARKET ANALYSIS BY AGE GROUP
    48. 6.48 INDIA MARKET ANALYSIS BY SEVERITY LEVEL
    49. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF ARTHRITIS
    50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    51. 6.51 JAPAN MARKET ANALYSIS BY AGE GROUP
    52. 6.52 JAPAN MARKET ANALYSIS BY SEVERITY LEVEL
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY SEVERITY LEVEL
    57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    59. 6.59 MALAYSIA MARKET ANALYSIS BY AGE GROUP
    60. 6.60 MALAYSIA MARKET ANALYSIS BY SEVERITY LEVEL
    61. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF ARTHRITIS
    62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    63. 6.63 THAILAND MARKET ANALYSIS BY AGE GROUP
    64. 6.64 THAILAND MARKET ANALYSIS BY SEVERITY LEVEL
    65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    67. 6.67 INDONESIA MARKET ANALYSIS BY AGE GROUP
    68. 6.68 INDONESIA MARKET ANALYSIS BY SEVERITY LEVEL
    69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF ARTHRITIS
    70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    71. 6.71 REST OF APAC MARKET ANALYSIS BY AGE GROUP
    72. 6.72 REST OF APAC MARKET ANALYSIS BY SEVERITY LEVEL
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF ARTHRITIS
    75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    76. 6.76 BRAZIL MARKET ANALYSIS BY AGE GROUP
    77. 6.77 BRAZIL MARKET ANALYSIS BY SEVERITY LEVEL
    78. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF ARTHRITIS
    79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    80. 6.80 MEXICO MARKET ANALYSIS BY AGE GROUP
    81. 6.81 MEXICO MARKET ANALYSIS BY SEVERITY LEVEL
    82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    84. 6.84 ARGENTINA MARKET ANALYSIS BY AGE GROUP
    85. 6.85 ARGENTINA MARKET ANALYSIS BY SEVERITY LEVEL
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY LEVEL
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF ARTHRITIS
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY LEVEL
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY LEVEL
    99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    101. 6.101 REST OF MEA MARKET ANALYSIS BY AGE GROUP
    102. 6.102 REST OF MEA MARKET ANALYSIS BY SEVERITY LEVEL
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 TO 2035 (USD Million)
    111. 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    113. 6.113 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
    115. 6.115 HEALTHCARE, BY SEVERITY LEVEL, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY SEVERITY LEVEL, 2024 TO 2035 (USD Million)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.2.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.3.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.3.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.4.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.4.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.5.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.5.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.6.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.6.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.7.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.7.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.8.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.8.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.9.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.9.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.10.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.10.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.11.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.11.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.12.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.12.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.13.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.13.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.14.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.14.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.15.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.15.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.16.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.16.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.17.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.17.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.18.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.18.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.19.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.19.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.20.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.20.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.21.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.21.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.22.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.22.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.23.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.23.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.24.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.24.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.25.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.25.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.26.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.26.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.27.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.27.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.28.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.28.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.29.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.29.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
      2. 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.30.3 BY AGE GROUP, 2025-2035 (USD Million)
      4. 7.30.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Type of Arthritis (USD Million, 2025-2035)

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Post-Traumatic Arthritis
  • Gout

Healthcare By Treatment Type (USD Million, 2025-2035)

  • Medication
  • Physical Therapy
  • Surgical Intervention
  • Assistive Devices

Healthcare By Age Group (USD Million, 2025-2035)

  • Children
  • Adults
  • Elderly

Healthcare By Severity Level (USD Million, 2025-2035)

  • Mild
  • Moderate
  • Severe